• Country: TAIWAN
  • Official Title: 執行長/教授
  • Department: 賽昂生醫股份有限公司/台北醫學大學

Speech Title

Bispecific Antibody-armed T-Cell Therapy : A Novel Weapon for Solid Tumors

CAR-T cell therapy has revolutionized the treatment of B-cell malignancies, but its application in T-cell lymphoma is still emerging. T-cell lymphoma presents unique challenges due to its heterogeneity, limited specific targets, and potential for “self-tolerance” issues. Current research focuses on identifying suitable targets, such as CD5 and CD4, while addressing safety concerns like cytokine release syndrome (CRS) and neurotoxicity. Early clinical trials show promise, but further investigation is needed to refine treatment protocols and improve long-term outcomes. Continued advancements in CAR-T technology and clinical insights are crucial for enhancing its efficacy and safety in T-cell lymphoma.